Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Mannkind Corp
(NQ:
MNKD
)
7.260
+0.170 (+2.40%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,766,780
Open
7.020
Bid (Size)
7.070 (2)
Ask (Size)
7.180 (68)
Prev. Close
7.090
Today's Range
7.010 - 7.300
52wk Range
3.170 - 7.325
Shares Outstanding
264,305,532
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
MannKind to Present at 2024 UBS Healthcare Conference
Today 16:15 EST
From
MannKind
Via
GlobeNewswire
MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases
November 04, 2024
From
MannKind
Via
GlobeNewswire
Performance
YTD
+85.20%
+85.20%
1 Month
+14.51%
+14.51%
3 Month
+38.81%
+38.81%
6 Month
+65.00%
+65.00%
1 Year
+97.28%
+97.28%
More News
Read More
MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024
October 31, 2024
From
MannKind
Via
GlobeNewswire
Lytham Partners Announces KOL Panels and Participating Companies for its Fall 2024 Investor Conference
September 30, 2024
Via
Newsfile
More Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza®)
September 30, 2024
From
MannKind
Via
GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
September 23, 2024
Via
Benzinga
MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
September 18, 2024
From
MannKind
Via
GlobeNewswire
MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference
September 10, 2024
From
MannKind
Via
GlobeNewswire
Kohl's Posts Upbeat Q2 Earnings, Joins Box, Waldencast, AeroVironment And Other Big Stocks Moving Higher On Wednesday
August 28, 2024
Via
Benzinga
MannKind to Present at Upcoming Conferences
August 27, 2024
From
MannKind
Via
GlobeNewswire
Kent Kresa to Retire from MannKind’s Board of Directors; Steven B. Binder to be Appointed to the Board
August 14, 2024
From
MannKind
Via
GlobeNewswire
MannKind (MNKD) Q2 2024 Earnings Call Transcript
August 07, 2024
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update
August 07, 2024
From
MannKind
Via
GlobeNewswire
MannKind Launches Educational Website to Raise Awareness of NTM Lung Disease
July 31, 2024
From
MannKind
Via
GlobeNewswire
MannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024
July 30, 2024
From
MannKind
Via
GlobeNewswire
"Rule Breaker Investing" Market Cap Game Show: Bill Mann vs. Bill Barker
June 27, 2024
Via
The Motley Fool
INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific Sessions
June 22, 2024
From
MannKind
Via
GlobeNewswire
Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions
June 05, 2024
From
MannKind
Via
GlobeNewswire
MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix
May 29, 2024
From
MannKind
Via
GlobeNewswire
MannKind (MNKD) Q1 2024 Earnings Call Transcript
May 09, 2024
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
MNKD Stock Earnings: MannKind Beats EPS, Beats Revenue for Q1 2024
May 08, 2024
Via
InvestorPlace
MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update
May 08, 2024
From
MannKind
Via
GlobeNewswire
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
May 06, 2024
From
MannKind
Via
GlobeNewswire
MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
May 01, 2024
From
MannKind
Via
GlobeNewswire
MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases
April 30, 2024
From
MannKind
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
